Flora Growth (NASDAQ:FLGC) versus iRadimed (NASDAQ:IRMD) Head to Head Review

Flora Growth (NASDAQ:FLGC) and iRadimed (NASDAQ:IRMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Flora Growth and iRadimed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
iRadimed	26.70%	23.45%	20.36%

Risk & Volatility

Flora Growth has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. Comparatively, iRadimed has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Insider & Institutional Ownership

36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by company insiders. Comparatively, 34.6% of iRadimed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Flora Growth and iRadimed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1	0	0	0	1.00
iRadimed	0	2	3	1	2.83

iRadimed has a consensus target price of $120.00, indicating a potential upside of 42.94%. Given iRadimed’s stronger consensus rating and higher possible upside, analysts plainly believe iRadimed is more favorable than Flora Growth.

Valuation and Earnings

This table compares Flora Growth and iRadimed”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61 million	0.06	-$15.91 million	($32.49)	-0.10
iRadimed	$86.34 million	12.43	$22.48 million	$1.79	46.90

iRadimed has higher revenue and earnings than Flora Growth. Flora Growth is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Summary

iRadimed beats Flora Growth on 14 of the 15 factors compared between the two stocks.

About Flora Growth

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.